Skip to: Content
Skip to: Site Navigation
Skip to: Search
THURSDAY, NOVEMBER 26, 2009
| Subscribe to Newser's RSS feeds RSS | Follow Newser on Twitter Twitter

NEWS ABOUT: Zyprexa

Zyprexa stories: 3 news summaries

Antipsychotic Drugs Triple Health Risks in Elderly

Dementia research finds even brief use is dangerous

May 27, 08 8:53 AM CDT
(Newser) - Elderly dementia patients given antipsychotic drugs, even briefly, are three times as likely to end up hospitalized or dead within a month, new research has found. The study looked at 40,000 elderly Canadians, half of them in nursing homes, and found that the drugs increased the risk of... More »

MORE ABOUT:
elderly • dementia • antipsychotic drugs • nursing homes • Zyprexa • Alzheimer's Disease

Eli Lilly Could Pay $1B Settlement

Fine for illegally promoting antipsychotic drug Zyprexa would be biggest ever

Jan 30, 08 5:40 PM CST
(Newser) - Drug-maker Eli Lilly could pay more than $1 billion to state and federal authorities to settle an investigation into how the company marketed an antipsychotic drug, the New York Times reports. In 2000-03, Lilly pushed doctors to prescribe Zyprexa as a treatment for age-related dementia—though the drug is approved... More »

MORE ABOUT:
pharmaceutical companies • Eli Lilly • settlement • Zyprexa

Big Pharma Faces Big Plunge

Profits will drop as patents expire, and chemical-based therapies are eclipsed by biotech

Dec 6, 07 4:50 AM CST
(Newser) - Patent protections on some of the pharmaceutical industry's best-selling drugs, like Lipitor, Plavix and Singulair, are due to expire in the next several years, and drug manufacturers have little in the pipeline to replace them. The drug companies will lose billions—as much as half their combined revenue—to generic... More »

MORE ABOUT:
Merck • pharmaceutical companies • GlaxoSmithKline • Pfizer • Eli Lilly • Zocor • Lipitor • Plavix • pharmaceutical industry • Zyprexa • Fosamax • Singulair • Cozaar • torcetrapib • drug manufacturer

3 Stories


from our news partners